[HTML][HTML] Olaparib plus bevacizumab as first-line maintenance in ovarian cancer
…, G Scambia, A Lortholary, F Marmé… - … England Journal of …, 2019 - Mass Medical Soc
Background Olaparib has shown significant clinical benefit as maintenance therapy in
women with newly diagnosed advanced ovarian cancer with a BRCA mutation. The effect of …
women with newly diagnosed advanced ovarian cancer with a BRCA mutation. The effect of …
Large-scale genotyping identifies 41 new loci associated with breast cancer risk
Breast cancer is the most common cancer among women. Common variants at 27 loci have
been identified as associated with susceptibility to breast cancer, and these account for ∼9…
been identified as associated with susceptibility to breast cancer, and these account for ∼9…
Palbociclib for residual high-risk invasive HR-positive and HER2-negative early breast cancer—the penelope-B trial
S Loibl, F Marmé, M Martin, M Untch… - Journal of clinical …, 2021 - ingentaconnect.com
PURPOSE About one third of patients with hormone receptor–positive, human epidermal
growth factor receptor 2–negative breast cancer who have residual invasive disease after …
growth factor receptor 2–negative breast cancer who have residual invasive disease after …
68Ga-FAPI PET/CT: tracer uptake in 28 different kinds of cancer
…, H Winter, PK Plinkert, F Marme… - Journal of Nuclear …, 2019 - Soc Nuclear Med
The recent development of quinoline-based PET tracers that act as fibroblast-activation-protein
inhibitors (FAPIs) demonstrated promising preclinical and clinical results. FAP is …
inhibitors (FAPIs) demonstrated promising preclinical and clinical results. FAP is …
Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay
…, T Höfner, M Sprick, M Scharpff, F Marmé… - Nature …, 2013 - nature.com
It has been hypothesized that carcinoma metastasis is initiated by a subpopulation of
circulating tumor cells (CTCs) found in the blood of patients. However, although the presence of …
circulating tumor cells (CTCs) found in the blood of patients. However, although the presence of …
Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials
…, C Solbach, J Huober, K Rhiem, F Marmé… - The Lancet …, 2021 - thelancet.com
Background The development of anti-HER2 antibody–drug conjugates opens new therapeutic
options for patients with breast cancer, including patients with low expression of HER2. …
options for patients with breast cancer, including patients with low expression of HER2. …
Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer
…, C Mulot, M Sanchez, B Burwinkel, F Marme… - Nature …, 2015 - nature.com
Genome-wide association studies (GWAS) and large-scale replication studies have identified
common variants in 79 loci associated with breast cancer, explaining ∼14% of the familial …
common variants in 79 loci associated with breast cancer, explaining ∼14% of the familial …
Prediction of breast cancer risk based on profiling with common genetic variants
…, MW Beckmann, B Burwinkel, F Marme… - Journal of the …, 2015 - academic.oup.com
Background: Data for multiple common susceptibility alleles for breast cancer may be combined
to identify women at different levels of breast cancer risk. Such stratification could guide …
to identify women at different levels of breast cancer risk. Such stratification could guide …
Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer
…, JJ Garcia, A Cox, V Shridhar, B Burwinkel, F Marme… - Nature …, 2013 - nature.com
TERT-locus SNPs and leukocyte telomere measures are reportedly associated with risks of
multiple cancers. Using the Illumina custom genotyping array iCOGs, we analyzed ∼480 …
multiple cancers. Using the Illumina custom genotyping array iCOGs, we analyzed ∼480 …
Systemic presence and tumor-growth promoting effect of ovarian carcinoma released exosomes
S Keller, AK König, F Marmé, S Runz, S Wolterink… - Cancer letters, 2009 - Elsevier
Exosomes are membrane vesicles that are released from many different cell types. Tumor
derived-exosomes play a role in immune suppression. We hypothesized that in ovarian …
derived-exosomes play a role in immune suppression. We hypothesized that in ovarian …